Histopathologic image of cutaneous neurofibroma obtained by biopsy
|Classification and external resources|
|ICD-10||D36.1 (ILDS D36.160)|
A neurofibroma is a benign nerve sheath tumor in the peripheral nervous system. Usually found in individuals with neurofibromatosis type I (NF1), an autosomal dominant genetically inherited disease, they can result in a range of symptoms from physical disfiguration and pain to cognitive disability. Neurofibromas arise from nonmyelinating-type Schwann cells that exhibit biallelic inactivation of the NF1 gene that codes for the protein neurofibromin. This protein is responsible for regulating the RAS-mediated cell growth signaling pathway. In contrast to schwannomas, another type of tumor arising from Schwann cells, neurofibromas incorporate many additional types of cells and structural elements in addition to Schwann cells, making it difficult to identify and understand all the mechanisms through which they originate and develop.
- 1 Subtypes of Neurofibroma
- 2 Etiology
- 3 Diagnosis
- 4 Non-drug treatments for neurofibroma
- 5 Drug treatment for neurofibroma
- 5.1 Drug treatment targets
- 5.2 Drug studies which demonstrated no effect
- 5.3 Drug studies currently active
- 6 See also
- 7 References
- 8 External links
Subtypes of Neurofibroma
Neurofibromas have been subdivided into two broad categories: dermal and plexiform. Dermal neurofibromas are associated with a single peripheral nerve, while plexiform neurofibromas are associated with multiple nerve bundles. According to the World Health Organization classification system, dermal and plexiform neurofibromas are grade I tumors. Plexiform neurofibroma are more difficult to treat and can transform into malignant tumors. Dermal neurofibroma do not become malignant.
- Discrete cutaneous neurofibromas: Sessile or pedunculated masses on the skin, which are fleshy and non-tender, and can vary in size.
- Discrete subcutaneous neurofibromas: Lie below and look like bumps on the skin, which can sometimes be tender.
- Deep nodular neurofibromas: Involving tissues and organs underneath the dermis, but otherwise resembling cutaneous and subcutaneous neurofibromas.
Age of onset
Dermal neurofibroma typically arise in the teenage years and are often associated with the onset of puberty. They continue to increase in number and size throughout adulthood, although there are limits to how big they get.
Dermal neurofibromas can lead to stinging, itching, pain and disfiguration.
Plexiform neurofibromas can grow from nerves in the skin or from more internal nerve bundles, and can be very large. Internal plexiform neurofibromas are very difficult to remove completely because they extend through multiple layers of tissue and the attempt would damage healthy tissue or organs.
Age of onset
Plexiform neurofibroma can cause disfigurement, neurological and other clinical deficits.
Plexiform neurofibromas have the potential to cause severe clinical complications if they occur in certain areas.
About 10% of plexiform neurofibromas undergo transformation into a malignant peripheral nerve sheath tumor (MPNST). The formation of malignant cancers from neurofibromas is associated with the loss of expression of the CDKN2A or TP53 gene in non-myelinating Schwann cells that also exhibit biallelic inactivation of the NF1 gene.
Neurofibromin 1 gene
The NF1 gene is composed of 60 exons spanning 350kb of genomic data, and maps to chromosomal region 17qll.2. This gene codes for neurofibromin which is a large 220-250 KDa cytoplasmic protein that is composed of 2,818 amino acids with three alternatively spliced exons (9a, 23a and 48a) in the encoding gene. The functional part of neurofibromin is a GAP, or GTPase-activating protein. GAP accelerates the conversion of the active GTP-bound RAS to its inactive GDP-bound form, inactivating RAS and reducing RAS-mediated growth signaling. Loss of RAS control leads to increased activity of other signaling pathways including RAF, ERK1/2, PI3K, PAK and mTOR-S6 kinase. It is suspected that this increased activity of downstream RAS pathways might work together to increase cell growth and survival. Genes that code for proteins that regulate cell growth, such as NF1 and TP53, are referred to as tumor suppressor genes. Neurofibromin has other growth-regulatory properties besides its ability to regulate RAS activity, but these other functions are poorly understood at this time.
There are two kinds of Schwann cells, myelinating and nonmyelinating. While myelinating Schwann cells cover large diameter (>1 micrometer) peripheral nervous system (PNS) axons with myelin, nonmyelinating Schwann cells encapsulate small diameter PNS axons with their cytoplasmic processes. Nonmyelinating Schwann cells are the neoplastic element in neurofibromas. This conglomeration of nonmyelinating Schwann cells and axons is called a Remak bundle.
While nonmyelinating Schwann cells are the origin of neurofibromas, the mutations that make them susceptible to this transformation occur in Schwann cell precursors during early nerve development. Mutated nonmyelinating Schwann cells do not form normal Remak bundles. Instead, they fail to properly surround and segregate target axons. It is unknown at this time why, if both types of Schwann cells exhibit bilallelic inactivation of the NF1 gene, only the nonmyelinating variety give rise to neurofibromas.
Loss of heterozygosity leads to loss of tumor suppressor function leads to neurofibroma formation
Neurofibromas arise from nonmyelinating Schwann cells that only express the inactive version of the NF1 gene, which leads to a complete loss of expression of functional neurofibromin. While one defective allele may be inherited, loss of heterozygosity (LOH) must occur before a neurofibroma can form; this is called the ‘two-hit hypothesis’. This LOH happens by the same mechanisms, such as oxidative DNA damage, that causes mutations in other cells.
Once a nonmyelinating Schwann cell has suffered inactivation of its NF1 genes, it begins to proliferate rapidly. This condition is called hyperplasia, which is cell growth beyond what is normally seen. However, despite increased numbers of nonmyelinating Schwann cells, there is no neurofibroma yet. In order for the neurofibroma to develop, cells that are heterozygous for the NF1 gene must be recruited to the site. It has been hypothesized that the proliferating nonmyelinating Schwann cells secrete chemoattractants such as the KIT ligand, and angiogenic factors such as the heparin-binding growth factor midkine. These chemicals promote the migration of different kinds of cells that are heterozygous for the NF1 gene into the hyperplastic lesions created by the nonmyelinating Schwann cells. These cell types include fibroblasts, perineurial cells, endothelial cells, and mast cells. The mast cells then secrete mitogens or survival factors that alter the developing tumor microenvironment and result in neurofibroma formation.
Dermal and plexiform neurofibromas differ in later development stages, but the details are unclear at this point.
Non-drug treatments for neurofibroma
Surgical treatment of dermal neurofibroma
Dermal neurofibromas are not usually surgically removed unless they are painful or disfiguring, because there are generally so many of them and they are not dangerous.
CO2 laser treatment for dermal neurofibroma
CO2 lasers have been used to remove dermal neurofibromas. In a paper titled Hypertrophic Scars After Therapy with CO2 Laser for Treatment of Multiple Cutaneous Neurofibromas Ostertag et al. said this about treatment by laser: “The cosmetic disfigurement is the most important issue in the decision to treat cutaneous symptoms of neurofibromatosis. Treating patients with extensive neurofibromas with [a] CO2 laser is still the best choice. However, it is strongly advised that a test treatment be performed to judge the effectiveness of the procedure and whether the developed scar is an acceptable trade-off.” 
Surgical treatment of plexiform neurofibroma
Removal of plexiform neurofibromas is difficult because they can be large and cross tissue boundaries. However, besides pain, plexiform neurofibromas are sometimes removed due to the possibility of malignant transformation.
The following examples show that plexiform neurofibromas can form anywhere and can make surgical resection difficult:
- A large plexiform neurofibroma in the leg of a 6-year-old male. The authors state: “Our case was operated, as both the cutaneous and deep branches of the peroneal nerve were involved causing pain and numbness in the leg, and because there was a possibility for malignant transformation, as growth in the mass was realized by the family members of the patient.” In layman’s terms, they decided to remove the neurofibroma because it was causing the boy pain and numbness in his leg, and because there was a possibility that it was undergoing a malignant transformation as his family noticed an increase in the tumor's size. The authors also note, “However, complete resection is quite difficult due to invasion of the tumor into the surrounding soft tissues.” 
- A neurofibroma on the left ventricle. The neurofibroma was removed and the patient’s mitral valve had to be replaced.
- A 14-year-old girl with NF1 was diagnosed with a neurofibroma involving her bladder, a rare location.
Radiation treatment of plexiform neurofibroma
Once a plexiform neurofibroma has undergone malignant transformation, radiation and chemotherapy can be used as treatment. However, radiation is generally not used as a treatment for plexiform neurofibromas because of concerns that this could actually promote malignant transformation. There has even been a documented case of a Schwannoma being induced from a neurofibroma due to radiation therapy.
Drug treatment for neurofibroma
There are many drug therapies under study for neurofibromas. These are in various stages of research; more time will be required to determine if these are viable options for the treatment of neurofibromas.
Drug treatment targets
ACE inhibitors have been proposed as a novel treatment of neurofibromas. ACE inhibitors are currently used to treat hypertension and congestive heart failure, to avert remodeling and reinfarction after myocardial infarction, and to ameliorate diabetic nephropathy and other renal diseases. ACE inhibitors work by indirectly down regulating TGF-beta, which is a growth factor that has been shown to influence the development of tumors.
Stabilisation of axon-Schwann cell interaction and reduction of mast cell infiltration
Based on the recent discovery that the nonmyelinating Schwann cells that make up Remak bundles are the origin of neurofibromas, it has been proposed that therapies for prevention and treatment be based on stabilizing the axon-Schwann cell interactions and reducing mast cell infiltration. As it appears that these elements are needed for neurofibroma formation, prevention or reduction could prove an effective treatment.
As of 2006, therapy for NF1 tumors had not been tested due to the lack of an appropriate NF1 tumor model.
Drug studies which demonstrated no effect
Tipifarnib (also known as drug R115777) inhibits the activation of RAS. This drug is a Farnesyltransferase inhibitor which inhibits the Ras kinase in a post translational modification step before the kinase pathway becomes hyperactive. It successfully passed phase one clinical trials but was suspended (NCT00029354) in phase two after showing no improvement over controls. 
Drug studies currently active
Pegylated Interferon (Peg-Intron)
- Malignant peripheral nerve sheath tumor
- Genetic disorder
- Watson syndrome
- Proteus syndrome
- Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. (2003). "Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells.". American Journal of Pathology 158 (2): 501–13. doi:10.1016/S0002-9440(10)63992-2. PMC 1850316. PMID 11159187.
- Miller RT (October 2004). "Immunohistochemistry in the differential diagnosis of schwannoma and neurofibroma" (PDF). Propath.
- "Case Based Pediatrics For Medical Students and Residents: Chapter XVIII.11. Neurofibromatosis", by Vince K. Yamashiroya, MD. August, 2002. Department of Pediatrics, University of Hawaii John A. Burns School of Medicine.
- Kluwe L, Hagel C, Mautner V (April 2007). "Neurofibroma".
- Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knöfel MT, Wenzel R, Fünsterer C. (2003). "Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma.". American Journal of Pathology 45 (9): 618–25. doi:10.1007/s00234-003-0964-6. PMID 12898075.
- MH Shen, PS Harper, M Upadhyaya. (1996). "Molecular genetics of neurofibromatosis type 1 (NF1)". Journal of Medical Genetics 33 (1): 2–17. doi:10.1136/jmg.33.1.2. PMC 1051805. PMID 8825042.
- Rubin JB, Gutmann DH. (2005). "Neurofibromatosis type 1 - a model for nervous system tumour formation?". Nature Reviews Cancer 5 (7): 557–64. doi:10.1038/nrc1653. PMID 16069817.
- Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR. (1993). "Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras.". Proceedings of the National Academy of Sciences of the USA 90 (12): 5539–43. doi:10.1073/pnas.90.12.5539. PMC 46756. PMID 8516298.
- Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, Zhu Y. (2008). "Induction of Abnormal Proliferation by Nonmyelinating Schwann Cells Triggers Neurofibroma Formation". Cancer Cell 13 (2): 117–28. doi:10.1016/j.ccr.2008.01.002. PMID 18242512.
- "Rare genetic condition tracked down with potential new biomarker". CORDIS News. 4 July 2011.
- Kolanczyk M, Mautner V, Kossler N et al. (2011). "MIA is a potential biomarker for tumour load in neurofibromatosis type 1". BMC Medicine 9: 82. doi:10.1186/1741-7015-9-82. PMC 3224593. PMID 21726432.
- Ostertag JU, Theunissen CC, Neumann HA. (2002). "Hypertrophic scars after therapy with CO2 laser for treatment of multiple cutaneous neurofibromas". Clinical Orthopaedics and Related Research 28 (3): 296–8. doi:10.1046/j.1524-4725.2002.01145.x. PMID 11896787.
- Packer RJ, Gutmann DH, Rubenstein A et al. (May 2002). "Plexiform neurofibromas in NF1: toward biologic-based therapy". Neurology 58 (10): 1461–70. doi:10.1212/wnl.58.10.1461. PMID 12041525.
- Cebesoy O, Tutar E, Isik M, Arpacioglu O. (2007). "A case of isolated giant plexiform neurofibroma involving all branches of the common peroneal nerve". Archives of Orthopaedic and Trauma Surgery 127 (8): 709–12. doi:10.1007/s00402-007-0303-1. PMID 17377797.
- Iino K, Matsumoto Y, Endo M et al. (2006). "Surgical treatment of a left ventricular neurofibroma". Journal of Cardiac Surgery 21 (3): 278–80. doi:10.1111/j.1540-8191.2005.00135.x. PMID 16684061.
- Meesa IR, Junewick JJ (August 2008). "Pelvic plexiform neurofibroma involving the urinary bladder". Pediatric Radiology 38 (8): 916. doi:10.1007/s00247-008-0865-2. PMID 18458838.
- Isler MH, Fogaça MF, Mankin HJ. (1996). "Radiation induced malignant schwannoma arising in a neurofibroma". Clinical Orthopaedics and Related Research 325 (325): 251–5. doi:10.1097/00003086-199604000-00031. PMID 8998885.
- Viskochil, David (2010). "Neurofibromatosis 1: Current Issues in Diagnosis, Therapy, and Patient Management" (PDF). Denver: Mountain States Genetic Foundation.
- Klesse, Laura (2010). "Current Therapies for Neurofibromatosis Type 1" (PDF). Denver: Mountain States Genetic Foundation.
- Namazi H. (2008). "ACE inhibitors: a novel treatment for neurofibroma". Clinical Orthopaedics and Related Research 15 (5): 1538–9. doi:10.1245/s10434-007-9737-5. PMID 18157575.
- Wetmore DZ, Garner CC (September 2010). "Emerging pharmacotherapies for neurodevelopmental disorders". Journal of Developmental and Behavioral Pediatrics 31 (7): 564–81. doi:10.1097/DBP.0b013e3181ee3833. PMC 2967570. PMID 20814256.
- Gottfried ON, Viskochil DH, Couldwell WT (January 2010). "Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications". Neurosurgical Focus 28 (1): E8. doi:10.3171/2009.11.FOCUS09221. PMID 20043723.
- Muir, David F. (April 2006). "Angiogenesis and Therapeutic Approaches to NF1 Tumors". University of Florida Gainesville. also available here
- Clinical trial number NCT00025454 for "R115777 in Treating Patients With Advanced Solid Tumors" at ClinicalTrials.gov
- "R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas"
- ["Tarceva/Rapamycin for Children With Low-Grade Gliomas With or Without Neurofibromatosis Type 1 (NF1" Children's Research Institute study NCT00901849
- Yang FC, Ingram DA, Chen S et al. (October 2008). "Nf1-dependent tumors require a microenvironment containing Nf1±- and c-kit-dependent bone marrow". Cell 135 (3): 437–48. doi:10.1016/j.cell.2008.08.041. PMC 2788814. PMID 18984156.
- "Gleevec Holds Potential As First Drug To Successfully Treat Neurofibromatosis, Scientists Report", Science Daily, October 31, 2008
- "Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas"
- Clinical trial number NCT00678951 for "Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults" at ClinicalTrials.gov National Cancer Institute
- "Peginterferon alpha-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1"
- Clinical trial number NCT00396019 for "Study of PEG-Intron for Plexiform Neurofibromas" at ClinicalTrials.gov
- Clinical trial number NCT00846430 for "Medical Treatment of "High-Risk" Neurofibromas" at ClinicalTrials.gov
- "A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas", National Institutes of Health study 08-C-0130
- Clinical trial number NCT00652990 for "Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I" at ClinicalTrials.gov
- Clinical trial number NCT00634270 for "A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)" at ClinicalTrials.gov
- "Drug Treatments on the Horizon – Clinical drug studies in NF", by Susan Toomey MS
- Clinical trial number NCT00727233 for "Sorafenib in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery" at ClinicalTrials.gov
- Ambrosini G, Cheema HS, Seelman S et al. (April 2008). "Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells". Mol. Cancer Ther. 7 (4): 890–6. doi:10.1158/1535-7163.MCT-07-0518. PMC 3267321. PMID 18413802.
- "Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas" National Cancer Institute study NCT00727233
- Wu J, Dombi E, Jousma E et al. (February 2011). "Preclincial testing of Sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging". Pediatr Blood Cancer 58 (2): 173–80. doi:10.1002/pbc.23015. PMID 21319287.
- Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y (March 2009). "Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1". The Tohoku Journal of Experimental Medicine 217 (3): 193–201. doi:10.1620/tjem.217.193. PMID 19282654.
- Ferner, RE; O'Doherty, MJ (Dec 2002). "Neurofibroma and schwannoma.". Current opinion in neurology 15 (6): 679–84. doi:10.1097/00019052-200212000-00004. PMID 12447105.